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Respiratorias, Hospital Universitario Virgen del Rocío, Sevilla, SpainAbstractThe diagnosis of Pneumocystis pneumonia (PCP) relies on microscopic visualization of Pneumocystis jirovecii organisms or DNA detection in
pulmonary specimens. This study aimed to assess the usefulness of (1–3)-β-D-glucan (BG), Krebs von den Lungen-6 antigen (KL-6),
lactate dehydrogenase (LDH) and S-adenosyl methionine (SAM) as serologic biomarkers in the diagnosis of PCP. Serum levels of BG, KL-
6, LDH and SAM were investigated in 145 Portuguese patients, 50 patients from the Netherlands, 25 Spanish patients and 40 Portuguese
blood donors. Data on clinical presentation, chest imaging and gasometry tests were available. PCP cases were conﬁrmed by microscopy
and PCR techniques. A cost-effectiveness analysis was performed. BG was found to be the most reliable serologic biomarker for PCP
diagnosis, followed by KL-6, LDH and SAM. The BG/KL-6 combination test was the most accurate serologic approach for PCP diagnosis,
with 94.3% sensitivity and 89.6% speciﬁcity. Although less sensitive/speciﬁc than the reference standard classic methods based on
bronchoalveolar lavage followed by microscopic or molecular detection of P. jirovecii organisms, the BG/KL-6 test may provide a less
onerous procedure for PCP diagnosis, as it uses a minimally invasive and inexpensive specimen (blood), which may be also a major
beneﬁt for the patient’s care. The BG/KL-6 combination test should be interpreted within the clinical context, and it may be used as a
preliminary screening test in patients with primary suspicion of PCP, or as an alternative diagnostic procedure in patients with
respiratory failure or in children, avoiding the associated risk of complications by the use of bronchoscopy.
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Pneumocystis pneumonia (PCP) is the most common acquired
immunodeﬁciency syndrome– indicative disease diagnosed
(25.4% and 23–31%, respectively) [1–4]. The rising numbers of
immunocompromised human immunodeﬁciency virus (HIV)-
negative patients susceptible to Pneumocystis jirovecii infectionClin Microbiol Infect 2015; 21: 379.e1–379.e10
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receiving allogeneic bone marrow or solid organ transplants; or
having autoimmune diseases) are an emerging concern [1,5].
PCP is difﬁcult to diagnose as a result of the associated
nonspeciﬁc signs and symptoms [2,6,7]. Because P. jirovecii
cannot be propagated in culture, microscopic visualization of
cysts or trophic forms in pulmonary specimens with cyto-
chemical staining or immunoﬂuorescent staining with mono-
clonal antibodies (IF/MAb) and/or DNA ampliﬁcation (PCR or
PCR-related protocols) are the standard procedures to
detect this microorganism [1,6,8–15]. Pulmonary specimens
obtained by invasive techniques such as bronchoscopy carry an
associated risk of complications in collection and are not easy
to obtain in patients with respiratory failure or in children
[2,11,16].
Alternative serum testing for the diagnosis of PCP has not
been established until now [17,18]. Previous reports suggested
that in patients with PCP, the serologic levels of (1–3)-β-D-
glucan (BG), Krebs von den Lungen-6 antigen (KL-6) and lactate
dehydrogenase (LDH) are increased, while the levels of S-
adenosyl methionine (SAM) are low [19–31]. The measure-
ment of serum BG, a cell wall polysaccharide of most fungi,
including P. jirovecii, is the most promising procedure for
establishing the serologic diagnosis of PCP [7,17–26]. KL-6
antigen, a mucin-like glycoprotein prominent on type II alve-
olar pneumocytes, was reported to be a potentially sensitive
indicator for interstitial pneumonitis [17,26,27]. The high serum
levels of LDH are likely to be a reﬂection of the underlying lung
injury [7,17,28].
A few studies suggest that SAM (metabolic intermediate in
methylation reactions and polyamine synthesis) is a promising
serologic biomarker for PCP diagnosis. In contrast to almost all
other pathogenic microorganisms, Pneumocystis species seem to
have a need for exogenous SAM. However, conﬂicting data
have been published reporting that Pneumocystis encodes a
functional SAM synthetase gene [24,29–31].
The aim of the present study was to evaluate the usefulness
of BG, LDH, KL-6 and SAM as serologic biomarkers in the
diagnosis of PCP.Materials and methodsPatient characteristics and sampling
A total of 260 participants (185 from Portugal, 50 from the
Netherlands and 25 from Spain) were included in this retro-
spective observational study. Specimens were collected be-
tween the years 2000 and 2013 for diagnostic purposes, before
patients started their therapeutic regimens (criterion for in-
clusion). Pulmonary (78 bronchoalveolar lavage (BAL) ﬂuid andClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infect67 induced sputum) and serum specimens were obtained from
145 patients (mean age, 40 years; range, 4–68 years, mal-
e:female ratio 2.1:1) living in the Lisbon area of Portugal. Of
these, 131 (90.3%) were HIV positive and 14 (9.7%) were HIV
negative (two patients with neoplasia, six organ transplant re-
cipients (two of whom were 4 years old) and four patients with
no available data to establish the cause of immunodeﬁciency).
Forty serum specimens were collected from Portuguese blood
donors (healthy individuals, weight of 50 kg or more and aged
between 18 and 65 years) and used as the control group. BAL
ﬂuids and serum specimens were collected from 50 patients in
whom PCP was suspected and who had an indication for BAL
(mean age, 59 years; range, 29–68 years; male:female ratio
2.3:1) living in the Leiden area of the Netherlands. Of these,
seven (14%) were HIV positive and 43 (86%) were HIV negative
(either immunocompromised after solid organ transplantation
or stem cell transplantation, or receiving immunosuppressive
drugs for autoimmune diseases). Twenty-ﬁve HIV-negative pa-
tients with chronic obstructive pulmonary disease (COPD)
(mean age, 70 years; range, 49–87 years, male:female ratio 24:1)
living in the Seville area of Spain contributed with 25 induced
sputa and serum specimens. After collection, blood specimens
were processed, and sera were immediately stored at −20°C. In
the present work, all specimens were studied retrospectively.
The study had the approval of the institutional review
boards/ethics committees from the involved institutions.
A clinical diagnosis of PCP was considered when at least two
of the following variables were present: symptoms such as
unproductive cough, fever and dyspnea; arterial partial pressure
of oxygen (PaO2) lower than 65 mm Hg; and chest radiographs
presenting ﬁne bilateral, perihilar interstitial shadowing [6,7,32].
Genomic DNA was extracted using the QIAamp DNA kit
(Qiagen, Germany). In the Portuguese patients, detection of
P. jirovecii organisms was performed by IF/MAb (MonoFluo kit
P. jirovecii; Bio-Rad, France) and nested PCR directed to the
P. jirovecii large-subunit mitochondrial rRNA (mtLSU rRNA) gene
[12,13,33]. In the Dutch patients, P. jirovecii was detected by
direct microscopy using histochemical staining (DM/HS) (Gi-
emsa and Grocott methenamine silver stains) and real-time
PCR directed to the dihydropteroate synthase (DHPS) gene
of P. jirovecii [14,17,19,24]. In the Spanish COPD patients,
detection of P. jirovecii was performed by nested PCR directed
to the mtLSU rRNA gene [33].
A PCP case was deﬁned when a patient fulﬁlled the clinical
diagnostic criteria for PCP and had positive IF/MAb or DM/HS
and/or positive PCR, or did not fulﬁl the clinical diagnostic
criteria for PCP but presented positive both IF/MAb or DM/HS
and PCR. Colonization or subclinical infections were described
not fulﬁlling the clinical diagnostic criteria for PCP with negative
IF/MAb or DM/HS and with positive PCR [2,7,13].ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 379.e1–379.e10
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All biomarker levels were measured by using commercial
quantitative microplate assays performed in the NanoQuant
Inﬁnite M200 Pro (Tecan, Switzerland) system according to the
manufacturer’s instructions. BG, KL-6, LDH and SAM levels
were determined by the Fungitell assay (Associates of Cape Cod
Inc., USA), enzyme-linked immunosorbent assay (ELISA) KL-6
antibody kit (Eisai Co., Japan), lactate dehydrogenase assay kit
(BioVision, USA) and ELISA SAM antibody kit (EIAab Co., China),
respectively. The cutoff reference values of the BG (100 pg/mL)
and LDH (350 U/L) assays were deﬁned according to previous
reports [7,14,19], while the cutoff values of the KL-6 (580 U/mL)
and SAM (50 nmol/L) assays were deﬁned according to the
sensitivity/speciﬁcity analysis of the present study.
Cost-effectiveness analysis
An examination of the costs and outcomes including sensi-
tivity, speciﬁcity, estimated costs, time load, specimen avail-
ability and technical observations was performed taking into
account methods available for the laboratory diagnosis of PcP.
Estimated costs per specimen included standard material for
diagnostic procedure such as reagents, kits and regular ma-
terial. Prices were estimated using catalogue and vendorTABLE 1. Laboratory data of 270 study participants
Characteristic
Portugal
PCP
positive
PCP negative
Total Colonizeda Other
(n [ 92) (n [ 53) (n [ 23) (n [ 3
HIV condition
Positive 86 (93.5) 45 (84.9) 19 (82.6) 26 (86.
Negative 6 (6.5) 8 (15.1) 4 (17.4) 4 (13.
Deﬁnitive diagnosis
of PCP
Microscopy/nested
PCR positive
92 (100) 23 (43.4) 23 (100) 0 (0)
Microscopy/nested
PCR negative
0 (0) 30 (56.6) 0 (0) 30 (100
Serologic BG test
Positive (100 pg/mL) 84 (91.3) 20 (37.7) 8 (34.8) 12 (40.
Negative (<100 pg/mL) 8 (8.7) 33 (62.3) 15 (65.2) 18 (60.
Serologic KL-6 test
Positive (580 U/mL) 65 (70.7) 13 (24.5) 7 (30.4) 6 (20.
Negative (<580 Um/L) 27 (29.3) 40 (74.5) 16 (69.6) 24 (80.
Serologic LDH test
Positive (350 U/L) 76 (82.6) 37 (69.8) 16 (69.6) 21 (70.
Negative (<350 U/L) 16 (17.4) 16 (30.2) 7 (30.4) 9 (30.
Serologic SAM testd (n = 45) (n = 25) (n = 10) (n = 15
Positive (50 nM) 28 (62.2) 12 (48.0) 5 (50.0) 7 (46.
Negative (>50 nM) 17 (37.8) 13 (52.0) 5 (50.0) 8 (53.
PCP, Pneumocystis pneumonia; HIV, human immunodeﬁciency virus; BG, (1–3)-β-D-glucan; K
methionine.
aColonized patients or subclinical infections (patients not fulﬁlling the clinical diagnostic crite
or direct microscopy using histochemical staining, and positive nested PCR).
bPatients not infected with Pneumocystis jirovecii presenting other pulmonary diseases.
cPulmonary specimens were not available for blood donors.
dIn the Portuguese population, SAM levels were calculated using a total of 82 samples (70 p
PCP-negative patients, of which 10 (14.3%) were colonized by P. jirovecii and 15 (21.4%) occ
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infquotes. Costs for diagnostic procedures did not include ex-
penses related to equipment acquisition or to maintenance
and salaries for laboratory workers. Because those factors are
highly variable between institutions or even between coun-
tries, they are not helpful in distinguishing the effective costs
of the diagnostic processes. The costs for BAL specimen
(bronchoscopy and BAL ﬂuid collection) and serum collection
were established from hospital clinics’ procedure price lists.
Data analysis
Statistical tests were applied to investigate associations at a
signiﬁcance level of 0.05 by SPSS version 20.0 software (IBM,
USA). Chi-square test and Fisher’s exact test were used to
investigate the association between qualitative/categorical vari-
ables. The Mann-Whitney U test was used to investigate the
differences between the distributions of the biomarker levels in
serum specimens across distinct categories of patients. The
Spearman rank-order correlation test was applied to study the
relationship between biomarker levels. Receiver operating
characteristic (ROC) curves, sensitivity, speciﬁcity, positive/
negative predictive values and positive/negative likelihood ratios
were calculated to assess the utility of BG, KL-6, LDH and SAM
serum levels for PCP diagnosis [7,21].Netherlands Spain
Blood
donorsc
PCP
positive
PCP negative/
other diseaseb Colonizedadiseaseb
0) (n [ 50) (n [ 31) (n [ 19) (n [ 25)
7) 0 (0) 3 (9.7) 4 (21.1) 0 (0)
3) 50 (100) 28 (90.3) 15 (78.9) 25 (100)
— 20 (64.5) 19 (100) 25 (100)
) — 11 (35.5) 0 (0) 0 (0)
0) 0 (0) 28 (90.3) 6 (31.6) 6 (24.0)
0) 50 (100) 3 (9.7) 13 (68.4) 19 (76.0)
0) 0 (0) 22 (71.0) 7 (36.8) 8 (32.0)
0) 50 (100) 9 (29.0) 12 (63.2) 17 (68.0)
0) 0 (0) 22 (71.0) 11 (57.9) 18 (72.0)
0) 50 (100) 9 (29.0) 8 (42.1) 7 (28.0)
) (n = 12)
7) 1 (8.3) 24 (77.4) 12 (63.2) 14 (56.0)
3) 11 (91.7) 7 (22.6) 7 (36.8) 11 (44.0)
L-6, Krebs von den Lungen-6 antigen; LDH, lactate dehydrogenase; SAM, S-adenosyl
ria for PCP with negative immunoﬂuorescent staining with monoclonal antibodies
atients and 12 blood donors), 45 (64.3%) PCP-positive patients and 25 (35.7%)
urred in patients with other pulmonary diseases.
ectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 379.e1–379.e10
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Of the 145 Portuguese patients studied, 92 (63%) were PCP
positive (fulﬁlled the clinical diagnostic criteria for PCP and had
positive microscopy and/or PCR for P. jirovecii, or did not
completely fulﬁl the clinical diagnostic criteria for PCP but had
positive microscopy) and 53 (37%) were PCP negative. Of the
53 PCP-negative patients, 23 (16%) were colonized by P. jirovecii
(did not fulﬁlled the clinical diagnostic criteria for PCP, with
negative microscopy and positive PCR for P. jirovecii) and 30
(21%) were not infected by P. jirovecii (negative microscopy and
PCR), instead having other pulmonary diseases. With respect to
the patients from the Netherlands, 31 (62.0%) were PCP pos-
itive and 19 (38.0%) were PCP negative with other pulmonary
diseases. In this population, no colonization was detected. The
25 (100%) Spanish COPD patients studied were PCP negativeFIG. 1. Graphic showing distribution of BG (a), KL-6 (b), LDH (c) and SAM (d
open circles; box-and-whisker plots show the 25th and 75th percentiles,
(whiskers). Asterisks represent points outside the range/scale in (b) and (c)
LDH: 2220 U/L, 2492 U/L). Different patient groups were categorized as PCP
and instead having other pulmonary disease (Other), blood donors (BD) a
(COPD). Patient groups were clustered according to country of origin.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectand colonized by P. jirovecii. The laboratory data of the partic-
ipants involved in the study are summarized in Table 1.
Serologic biomarkers
The statistical analysis testing the differences in the distribution
of the biomarkers between the patient groups are depicted in
Fig. 1. Among the Portuguese patients, the serum levels of BG,
LDH and KL-6 were signiﬁcantly higher in the PCP-positive
patients than in the PCP-negative patients, which included the
patients colonized by P. jirovecii and the patients not infected by
P. jirovecii, instead presenting other pulmonary diseases (p
<0.001 for BG and KL-6; p 0.004 for LDH). The SAM levels
showed no statistically signiﬁcant differences between patients
with and without PCP (Table 2, Fig. 1). The ROC curves
demonstrated that BG was the most promising/accurate
biomarker, followed by KL-6 and LDH (Fig. 2). The Spearman
rank correlation coefﬁcient analysis found statistically signiﬁcant
correlations between the serum levels of BG and KL-6 (p) levels in sera of different patient groups studied. Points are depicted as
median (horizontal line within boxes) and 10th and 90th percentiles
(KL-6: 5792 U/mL, 6197 U/mL, 7717 U/mL, 8946 U/mL, 14 286 U/mL;
positive (PCP), colonized by P. jirovecii (Colon.), not infected by P. jirovecii
nd HIV-negative patients with chronic obstructive pulmonary disease
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 379.e1–379.e10
TABLE 2. Serologic biomarkers median levels in different clinical groups
Country Patient/participant group (n, %)
Median BG
level (pg/mL)
Median KL-6
level (U/mL)
Median LDH
level (U/L)
Median SAM
level (nM)a
Portugal PCP positive (92, 63%) 333 969 707 38
PCP negative (53, 37%) 52 437 420 60
Colonized (23, 16%) 73 409 474 55
Other pulmonary disease (30, 21%) 41 440 419 60
Blood donors (negative control) (37, 100%) 31 230 141 75
Netherlands PCP positive (31, 62.0%) 411 585 423 43
PCP negative, other pulmonary disease (19, 38.0%) 69 257 394 46
Spain PCP negative colonized (25, 100%) 94 297 383 49
PCP, Pneumocystis pneumonia; BG, (1–3)-β-D-glucan; KL-6, Krebs von den Lungen-6 antigen; LDH, lactate dehydrogenase; SAM, S-adenosyl methionine.
aIn the Portuguese population, median SAM levels were calculated using a total of 82 serum specimens (70 patients and 12 blood donors), 45 (64.3%) PCP-positive patients and 25
(35.7%) PCP-negative patients, of which ten (14.3%) were colonized by Pneumocystis jirovecii and 15 (21.4%) occurred in patients who presented other pulmonary diseases.
CMI Esteves et al. Diagnosis of Pneumocystis pneumonia 379.e5<0.001, rho = 0.387), BG and LDH (p 0.041, rho = 0.170) and
KL-6 and LDH (p 0.025, rho = 0.187). The BG/KL-6 combi-
nation test was found to be the most sensitive/speciﬁc approach
for serologic diagnosis of PCP in the Portuguese population
(Table 3).
In the population from the Netherlands, the serum levels of
BG, LDH and KL-6 were also higher among PCP-positive pa-
tients. However, only the BG levels were signiﬁcantly increased
in those patients (p <0.001). Again, a similar distribution of
SAM levels was observed between patients with and without
PCP (Table 2, Fig. 1). The ROC curves and the sensitivity/
speciﬁcity analysis conﬁrmed that the most promising/accurate
biomarker was the BG, followed by KL-6 and LDH (Table 3,FIG. 2. ROC curves for BG, KL-6 and LDH assay tests in overall
population. Areas under the curve (AUC) were 89.5% for BG (95%
conﬁdence interval (CI) 85.1–93.9), 77.2% for KL-6 (95% CI 71.5–83.0)
and 74.8% for LDH (95% CI 68.8–80.7). All the results were statistically
signiﬁcant (p <0.001), rejecting the null hypothesis that the distribution
of these biomarkers is the same for patients with and without PCP.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InfFig. 2). The Spearman rank correlation coefﬁcient analysis
revealed a statistically signiﬁcant correlation between the
serum levels of BG and KL-6 (p 0.05, rho = 0.279), suggesting
the BG/KL-6 test to be the most robust approach for serologic
diagnosis of PCP.
No statistically signiﬁcant differences in the biomarker levels
were observed between the HIV-positive (131, 90.3%) and
HIV-negative (14, 9.7%) groups from the Portuguese popula-
tion. The same was observed between the HIV-positive (seven,
14.0%) and HIV-negative (43, 86.0%) patients from the
Netherlands. As a result of the asymmetric distribution of the
HIV patients, both populations were pooled together, which
allowed us to investigate the differences in the distribution of
biomarker levels among HIV-positive (138, 70.8%) and HIV-
negative (57, 29.2%) patients. Except for LDH, no statistically
signiﬁcant differences were observed in the biomarker levels
among these two groups. The LDH levels were observed to be
higher in HIV-positive patients (median, 601 U/L) than in HIV-
negative patients (median, 420 U/L) (p <0.001).
Considering all the populations studied as a pool (overall
population), the distributions of the four biomarker levels were
signiﬁcantly different between the PCP-positive and PCP-
negative patients (p <0.001 for BG, KL-6 and LDH; p 0.003
for SAM), rejecting the null hypothesis that the distribution of
these biomarkers is the same for patients with and without
PCP. The ROC curves and the sensitivity/speciﬁcity analysis
conﬁrmed the BG measurement to be the most accurate single
test for PCP diagnosis, followed by KL-6 and LDH (Table 3,
Fig. 2). Statistically signiﬁcant correlations were detected be-
tween the serum levels of BG and KL-6 (p <0.001, rho = 0.468)
and between BG and LDH (p <0.001, rho = 0.386). The BG/KL-
6 combination test was conﬁrmed to be the most sensitive/
speciﬁc approach for serologic diagnosis of PCP, presenting an
overall sensitivity of 94.3% and speciﬁcity of 89.6% (Table 3).
The comparison analysis between the laboratory diagnostic
methods for PCP diagnosis is summarized in Table 4. These
data brieﬂy report the most important variables, such as
sensitivity and speciﬁcity, operational and time costs, usefulectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 379.e1–379.e10
TABLE 3. Evaluation of biomarker assays and combination tests for diagnosis of PCP
Population Measure
Serologic biomarker assay test Combination testa
BG KL-6 LDH SAM BG/KL-6 BG/LDH KL-6/LDH
n 145 145 145 70 95 100 86
Sensitivity (%) 91.5 71.7 82.6 62.2 95.3 97.2 89.1
Speciﬁcity (%) 62.4 73.6 30.2 52.0 80.6 42.9 54.5
Portugal PPV (%) 80.8 82.5 67.3 70.0 91.0 78.8 85.1
NPV (%) 80.5 60.0 50.0 43.3 89.3 75.6 63.2
PLR 2.422 2.716 1.183 1.296 4.912 1.702 1.958
NLR 0.140 0.384 0.576 0.727 0.058 0.065 0.200
p <0.001 <0.001 >0.05 >0.05 <0.001 <0.001 <0.001
n 50 50 50 50 36 33 26
Sensitivity (%) 90.3 71.0 71.0 77.4 91.3 95.2 88.2
Speciﬁcity (%) 68.4 63.2 42.1 36.8 76.9 66.7 55.6
Netherlands PPV (%) 82.4 75.9 66.7 66.7 87.5 83.3 78.9
NPV (%) 81.2 57.1 47.1 50.0 83.3 88.9 71.4
PLR 2.858 1.929 1.226 1.225 3.952 2.859 1.986
NLR 0.142 0.459 0.689 0.614 0.113 0.072 0.212
p <0.001 0.018 >0.05 >0.05 <0.001 <0.001 0.028
n 260 260 260 260 183 182 167
Sensitivity (%) 91.1 71.5 79.7 68.4 94.3 96.8 88.9
Speciﬁcity (%) 76.6 78.8 51.8 51.9 89.6 71.9 74.4
Overallb PPV (%) 77.8 75.2 59.8 57.1 89.1 78.3 76.6
NPV (%) 90.5 75.5 74.0 63.6 94.5 95.5 87.7
PLR 3.893 3.373 1.653 1.422 9.067 3.445 3.473
NLR 0.116 0.362 0.392 0.609 0.064 0.044 0.149
p <0.001 <0.001 <0.001 0.010 <0.001 <0.001 <0.001
PCP, Pneumocystis pneumonia; BG, (1–3)-β-D-glucan; KL-6, Krebs von den Lungen-6 antigen; LDH, lactate dehydrogenase; SAM, S-adenosyl methionine; PPV, positive predictive
value; NPN, negative predictive value; PLR, positive likelihood ratio; NLR, negative likelihood ratio.
Cutoff values: 100 pg/mL (BG); 580 U/mL (KL-6); 350 U/L (LDH); 50 nM (SAM).
aCombination tests (BG/KL-6, BG/LDH and KL-6/LDH): positive when both biomarker levels were indicative for PCP, negative when both biomarker levels were below the
cutoff for PCP and indeterminate when either biomarker assay yielded contradictory results. SAM was not considered in the combination tests because of its lack of diagnostic
robustness.
bIncludes all groups studied: Portuguese PCP-positive and PCP-negative patients (patients colonized by Pneumocystis jirovecii and patients not infected by P. jirovecii presenting
other pulmonary disease), and blood donors; Dutch PCP-positive and PCP-negative patients; Spanish COPD patients colonized by P. jirovecii.
379.e6 Clinical Microbiology and Infection, Volume 21 Number 4, April 2015 CMIspecimens and beneﬁts and disadvantages implicated in the
laboratory diagnostic procedures available for P. jirovecii
detection and PCP diagnosis in clinical laboratory.DiscussionIn this retrospective observational study, the usefulness of four
serologic biomarkers (BG, KL-6, LDH and SAM) for the diag-
nosis of PCP was assessed. The most promising result when
using a single biomarker measurement was achieved with the
BG test, followed by KL-6, LDH and SAM. The performance
characteristics of the BG test in association with the KL-6 test
in the sera from HIV-positive and immunocompromised HIV-
negative patients was encouraging.
The high levels of BG among PCP-positive patients (p
<0.001) provide additional data to the observations of previous
studies that reported BG to be the most reliable biomarker for
serologic diagnosis of PCP [21,25]. The present results are
consistent with a previous report on the usefulness of BG levels
for PCP diagnosis in Portuguese HIV-positive patients in which
the sensitivity and speciﬁcity of the BG test (cutoff value of
100 pg/mL) were 89.9% and 71.0%, respectively [7]. Despite
being a structural molecule of the P. jirovecii cell wall, BG is not a
species-speciﬁc marker, instead presenting a panfungal char-
acter, which is one of the explanations for the false-positiveClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectﬁndings and the relatively low speciﬁcity rates for the diag-
nosis of PCP [7,18,21]. Additionally, it has been suggested by
others that false-positive ﬁndings may be caused by the
administration of certain agents that are ﬁltered through cel-
lulose membranes [22]. A previous study suggested that the
serum concentrations of BG may be higher in HIV-positive PCP
patients than in HIV-negative PCP patients. Those authors
associated these differences with the fact that the number of
P. jirovecii organisms in the lungs of HIV-positive PCP patients is
usually higher compared to that in HIV-negative PCP patients,
thus questioning the reliability of the BG test for the diagnosis
of PCP in immunocompromised HIV-negative patients [26].
Another study showed that higher BG levels may be found in a
HIV-negative PCP population with hematologic malignancies
than in a HIV-positive PCP population [19]. None of those
ﬁndings was conﬁrmed in the present study because no sta-
tistically signiﬁcant differences in the BG levels were observed
between the groups of HIV-positive and HIV-negative patients.
The KL-6 levels were signiﬁcantly increased in patients with
PCP (p <0.001) compared to PCP-negative patients; this was
the case because high levels of this molecule in serum are
known to be an indicator of interstitial lung diseases and acute
lung injury. The present results are consistent with those
previously described using KL-6 as biomarker for PCP diag-
nosis, in which elevated levels of KL-6 were statistically asso-
ciated with PCP positivity [17,26]. Because KL-6 is a hostious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 379.e1–379.e10
TABLE 4. Laboratory methods for Pneumocystis jirovecii detection, including worldwide microscopic, molecular and serologic/biochemical standard technical procedures for
P. jirovecii detection
Method Technique Sensitivitya Speciﬁcitya
Estimated cost
per sample, US$ (V)
(sample type)b
Approximate
time load
(hours)c
Most suitable
specimens (also
available specimens) Observations
Microscopy GMS 82% (BAL) 98% (BAL) 140.30 (102.9) (BAL) 3 BAL or biopsy Needs experienced/qualiﬁed microscopist; needs invasive and expensive samples;
cumbersome protocol; identiﬁcation of cysts; recommended combination with Giemsa or
Giemsa-like stains; allows semiquantiﬁcation methods; optical microscope
TBO 80% (BAL) 100% (BAL) 129.10 (94.7) (BAL) 2 BAL or biopsy Needs experienced/qualiﬁed microscopist; needs invasive and expensive samples;
identiﬁcation of cysts; recommended combination with Giemsa or Giemsa-like stains;
allows semiquantiﬁcation methods; optical microscope
Giemsa (or DQ) 75% (BAL) 100% (BAL) 130.50 (95.7) (BAL) 1 BAL or biopsy Needs experienced/qualiﬁed microscopist (very difﬁcult to read); needs invasive and
expensive samples; identiﬁcation of trophic forms and intracystic bodies; recommended
combination with GMS or TBO; allows semiquantiﬁcation methods; optical microscope
IF/MAb 100% (BAL) 100% (BAL) 138.50 (101.6) (BAL) 2 BAL, IS or biopsy Excellent sensitivity/speciﬁcity; easy to read; needs invasive and expensive samples; allows
semiquantiﬁcation methods; needs expansive/speciﬁc equipment (ﬂuorescence
microscope)
Molecular PCR nested 100% (BAL) 89% (BAL) 142.80 (104.7) (BAL) 8 BAL, IS or biopsy
(OW, ES, NPA)
Needs experienced/qualiﬁed staff; needs invasive and expensive samples; alternative
noninvasive samples may be used; detection of low fungal burdens (e.g. colonized patients);
possible false-positive ﬁndings; allows further genotyping; needs expensive/speciﬁc
equipment (thermocycler)
RT-qPCR 99% (BAL) 80% (BAL) 139.90 (107.0) (BAL) 4 BAL, IS or biopsy
(OW, ES, NPA)
High-throughput format; needs experienced/qualiﬁed staff; needs invasive and expensive
samples; alternative noninvasive samples may be used; possible false-positive ﬁndings;
detection of low fungal burdens (e.g. colonized patients); allows quantiﬁcation; needs
expensive/speciﬁc equipment (real-time apparatus)
Serologic/
biochemical
BG 91.1% (serum) 63.9% (serum) 23.40 (24.0) (serum) 3 Serum High-throughput format; minimally invasive and inexpensive samples; positive results in other
fungal infections (false-positive ﬁndings); recommended conﬁrmation of results with GMS/
Giemsa, TBO/Giemsa or IF/MAb; not quantitative; needs expensive/speciﬁc equipment
(microplate reader)
KL-6 71.5% (serum) 70.8% (serum) 33.30 (24.4) (serum) 2.5 Serum High-throughput format; minimally invasive and inexpensive samples; positive results in other
interstitial lung diseases (false-positive ﬁndings); needs combination with GMS/Giemsa,
TBO/Giemsa or IF/MAb; not quantitative; needs expensive/speciﬁc equipment (microplate
reader)
LDH 79.7% (serum) 33.3% (serum) 6.00 (4.4) (serum) 2 Serum High-throughput format; minimally invasive and inexpensive samples; positive results in organ
damage cases (false-positive ﬁndings); needs combination with GMS/Giemsa, TBO/Giemsa
or IF/MAb; not quantitative; needs expensive/speciﬁc equipment (microplate reader)
BG/KL-6 94.3% (serum) 89.6% (serum) 52.60 (45.4) (serum) 5.5 Serum High-throughput format; minimally invasive and expensive samples; not quantitative; needs
expansive/speciﬁc equipment (microplate reader)
GMS, Grocott methenamine silver stain; TBO, Toluidine Blue O; DC, Diff-Quick; IF/MAb, immunoﬂuorescent staining with monoclonal antibodies; RT-qPCR, real-time (quantitative) PCR; BG, (1–3)-β-D-glucan quantiﬁcation assay; KL-6,
Krebs von den Lungen-6 antigen quantiﬁcation assay; LDH, lactate dehydrogenase quantiﬁcation assay; BG/KL-6/CD, combination test using BG and KL-6 serum levels in association with clinical data/parameters; BAL, bronchoalveolar
lavage; IS, induced sputum; NPA, nasopharyngeal aspirate; OW, oropharyngeal wash; ES, expectorated sputum.
aSensitivity and speciﬁcity were classiﬁed based on Calderón et al. [6] and Harris et al. [36] (GMS, TBO, Giemsa or Giemsa-like, IF/MAb, PCR nested and RT-qPCR), and on data from the present study (BG, KL-6, LDH and BG/KL-6).
bEstimated costs per sample include sample collection (BAL ﬂuid or serum) and laboratorial technical procedure.
cApproximate time load was estimated on the basis of data from the present study considering one specimen.
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and bronchiolar epithelial cells, it may be more sensitive to
underlying interstitial lung disease rather than a speciﬁc marker
of P. jirovecii infection. This may be the cause for some false-
positive ﬁndings [26].
In the present study, the levels of LDH were signiﬁcantly
higher in PCP-positive patients than in patients without PCP
(p <0.001). LDH is a host molecule widely expressed in hu-
man tissues. This enzyme is released into the bronchoalveolar
space upon damage of the cytoplasmic cell membrane. The
serum levels of LDH are known to be elevated in patients with
PCP. This is likely to be a reﬂection of the underlying lung
injury and inﬂammation due to P. jirovecii and/or other path-
ogens present in the lung. Thus, the occurrence of false-
positive ﬁndings and the low speciﬁcity rate of LDH as a
diagnostic biomarker of PCP may be explained by the fact that
this enzyme is a nonspeciﬁc indicator of organ damage and
that high levels of LDH may be detected as a result of other
lung infections or diseases and/or a variety of extrapulmonary
disorders [17,28]. This is in accordance with recent obser-
vations in a Portuguese HIV-positive population, in which the
LDH test (cutoff value of 350 U/L) presented a sensitivity of
91.3% and a very low speciﬁcity of 35.5% for diagnosis of PCP
[7]. Even though LDH is often used as a nonspeciﬁc marker
for PCP, the present sensitivity/speciﬁcity results suggest that
the measurement of this enzyme may result in failure in
diagnostic procedures.
Although a few studies have claimed that SAM is an accurate
biomarker for PCP, the present results do not corroborate
those investigations. A previous study reported sensitivity and
speciﬁcity rates greater than 90% in HIV-positive PCP patients
when using this biomarker [29,30]. More recently, the utility of
SAM as an indicator for PCP was evaluated in immunocom-
promised HIV-negative patients from the Netherlands, in which
its measurement in serum was unable to distinguish between
PCP-positive and PCP-negative cases [24]. Despite the fact that
in the present study serologic concentrations of SAM were
observed to be slightly decreased in patients with PCP (p
0.003), the sensitivity/speciﬁcity analysis demonstrated that this
biomarker consistently failed to discriminate between patients
with and without PCP, revealing very low diagnostic robust-
ness. These differences may be due to the use of distinct lab-
oratory methodologies and sampling (high-performance liquid
chromatography and plasma were used in previous studies
instead of ELISA and serum) [29,30]. Additionally, this bias may
be caused by differences in P. jirovecii burdens and by factors
such as poor nutrition, medical conditions or other inherent
variables (e.g. coexisting pulmonary malignancies), thus affecting
the serum levels of this metabolite in a way that compromises
its reliability as a diagnostic tool [24,29]. The high cost of theClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectplasma SAM assay (US$300, V224.9 per sample specimen) is
also an important limitation [29].
No statistically signiﬁcant differences in the distribution of
BG and KL-6 levels between the PCP-positive patients from
Portugal and from the Netherlands were found. The same was
observed for the PCP-negative patients from these two
geographical origins. Also, no statistically signiﬁcant differences
in the BG and KL-6 level distributions were observed between
the colonized Portuguese patients and the colonized Spanish
COPD patients (Fig. 1). These data enhance the hypothesis that
both molecules may be used for PCP serologic screening, in-
dependent of the subject’s geographical location.
A major problem in the diagnosis of PCP is the distinction
between P. jirovecii colonization and PCP. Recent studies suggest
that serum biomarker levels may be useful in distinguishing
those clinical conditions, but none of them determined a
deﬁnitive optimal cutoff limit to be used safely [15,23,34,35]. In
one study, neither BG nor KL-6 was useful for detecting
P. jirovecii colonization. Although not statistically signiﬁcant, BG
levels measurement (PCP cases: 32.8 ± 35.1 pg/mL; coloniza-
tion cases: under the detection limit of the Wako β-glucan test
(Waco Pure Chemical Industries, Japan)) and T CD4+
lymphocyte count (PCP cases: 397.1 ± 151.6 cells/μL; coloni-
zation cases: 651.6 ± 565.6 cells/μL) showed an encouraging
approach for distinguishing P. jirovecii colonization from PCP
[23]. Other authors observed that combining quantiﬁcation of
P. jirovecii DNA in pulmonary specimens (cutoff values of
1.6 × 103 and 2 × 104 copies/μL, using the TaqMan Gene
Expression assay targeting the mtLSU rRNA gene (Applied Bio-
systems, USA)) with serum BG levels (threshold 100 pg/mL,
Fungitell assay) may be promising for the differential diagnosis
of PCP and P. jirovecii colonization [15]. In a recent research
work, a cutoff level for discrimination between PCP and
P. jirovecii colonization was suggested (33.5 pg/mL; Wako
β-glucan test) [35]. However, the present results found no
signiﬁcant differences in the distribution of BG levels between
the groups of colonized patients (Portuguese colonized patients
and Spanish COPD colonized patients) and the patients without
P. jirovecii infection with other pulmonary diseases, demon-
strating that, until now, there is no biochemical test or sero-
logic biomarker that clearly and safely allows differentiation of
P. jirovecii colonization from PCP.
The cost-effectiveness study of the diagnostic options for
PCP revealed that the most accurate methods are costly, while
the less onerous ones often lack sensitivity or speciﬁcity
(Table 4) [1,2,6,36]. The most accurate diagnostic procedure
(reference standard) is the classic microscopic observation of
P. jirovecii organisms in BAL specimens (IF/MAb, or Grocott
methenamine silver stain or Toluidine Blue O stain in combi-
nation with Giemsa or Giemsa-like examinations) [1,6,19,24].ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 379.e1–379.e10
CMI Esteves et al. Diagnosis of Pneumocystis pneumonia 379.e9Molecular detection of P. jirovecii tends to increase the sensi-
tivity of P. jirovecii detection in clinical specimens, establishing
earlier PCP diagnosis and detecting low fungal burdens
[1,2,19,36]. As shown, despite applying less onerous techniques
for P. jirovecii detection than the serologic approaches, the need
for bronchoscopy increases the ﬁnal costs of the classic diag-
nostic procedures. Instead of the highly sensitive and speciﬁc
values of the reference standard methods (BAL followed by
microscopy), until now, the serologic diagnosis of PCP is
compromised, mainly as a result of the lack of speciﬁcity.
The association measurement of BG and KL-6 was found to
be the most sensitive (94.3%) and speciﬁc (89.6%) protocol for
serologic diagnosis of PCP. The cost-effectiveness comparison
demonstrated that the BG/KL-6 protocol is less expensive than
the classic diagnostic procedures with bronchoscopy. In addi-
tion, the use of a minimally invasive specimen is a beneﬁt to
patient care. However, a major question emerges: Can the BG/
KL-6 test be performed by a standard hospital laboratory? The
procedure has an estimated cost of US$52.60 (V45.4) per
specimen, including the blood draw. Most community hospitals
do not have speciﬁc equipment and/or specialized personnel
with the expertise to perform the BG and KL-6 assays. It is thus
proposed that these tests be centralized in referral laboratories,
allowing standardization of protocols and cost savings due to
economies of scale. A previous study suggested that BG in as-
sociation with LDH and clinical data may be used as an
adjunctive preliminary screening test to diagnose PCP with
92.8% sensitivity and 83.9% speciﬁcity [7]. Still, these results are
dependent on speciﬁc clinical parameters, which may not be
always available. The estimated cost for the BG/LDH test is
US$25.30 (V25.4), lower than the one estimated for the BG/
KL-6 test, estimated in US$52.60 (V45.4), mainly as a result
of the low cost of the LDH assay. Although the BG/LDH test in
association with clinical parameters may be promising as an
alternative tool for PCP serologic diagnosis, this approach is
valid only in clinics or points of care where PaO2 or chest ra-
diographs can be accomplished, as demonstrated in a previous
report [7].
On the basis of our results, we propose a serologic method
as a complementary/indicative test for PCP based on the
measurement of BG and KL-6 levels in patients with advanced
immunosuppression and clinical signs and symptoms indicative
of PCP. The BG/KL-6 combination test should not be used as a
single test for PCP diagnosis, and it must be interpreted within
the clinical context. This combination of serologic methods will
not replace the classic reference standard diagnostic pro-
cedures for PCP. Nevertheless, we hypothesize that it may be
used as a preliminary screening test in patients with primary
suspicion of PCP, as an alternative diagnostic procedure in
patients with respiratory failure or even in children in whomClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infinvasive procedures for specimen collection are not easy to
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